Skip to main content
OpenTrials
Completed

NCT Number: NCT05904509

Insulin Resistance in Atopic Dermatitis Patients

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Glucose Metabolism Disorders Hyperinsulinism Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

2 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bezmialem Vakif University Hospital

Istanbul, Turkey (Türkiye)

About this study

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis. EASI and SCORAD values and disease duration of atopic dermatitis patients are calculated during the examination. HOMA-IR blood test result is compared with the results.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Atopic dermatitis patients confirmed by a dermatologist

Exclusion criteria

  • patients younger than 2 years
  • patients older than 80 years
  • Atopic dermatitis patients without HOMA-IR result

Treatment and study plan

Primary outcomes

  1. HOMA-IR

    Time frame: 12 months

    Patients' blood test show the result of fasting insulin (microU/L) x fasting glucose (mmol/L)/22.5

  2. SCORAD index

    Time frame: 12 months

    Severity scoring of atopic dermatitis is calculated for each patient in the study. 6 intensity items (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness); 2 subjective symptoms(itch, sleeplessness); body surface area are studied. Max score is 103.

  3. EASI index

    Time frame: 12 months

    Eczema Area and Severity Index is calculated for each patient in the study. Body surface area, 4 intensity items(erythema, induration, excoriation, lichenification) are studied. Max score is 72.

  4. Duration of the disease

    Time frame: 12 months

    The time from the first onset of symptoms of the disease to the present. The relationship between insulin resistance and disease duration is examined

Sponsors and collaborators

Lead sponsor

Bezmialem Vakif University

Other

Registry information

Official study title

The Relationship Between Insulin Resistance and Disease Severity and Duration in Atopic Dermatitis Patients

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 15, 2023
Registry last updated
Feb 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.